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Abstract: Azole resistance in Aspergillus fumigatus is most frequently conferred by mutations in
the cyp51A gene encoding 14α-sterol demethylases. TR34/L98H and TR46/Y121F/T289A are the
two most common mutations associated with environmental resistance selection. We studied the
minimal inhibitory concentration (MIC) distribution of clinical A. fumigatus isolates to characterize the
Clinical and Laboratory Standards Institute (CLSI) susceptibility profiles of isolates with the wild-type
(WT) cyp51A genotype, and isolates with the TR34/L98H and TR46/Y121F/T289A cyp51A mutations.
Susceptibility testing was performed according to CLSI M38-A2. The MICs of 363 A. fumigatus isolates
were used in this study. Based on the CLSI epidemiological cut-off values (ECVs), 141 isolates were
phenotypically non-WT and 222 isolates had a phenotypically WT susceptibility. All isolates with the
TR34/L98H mutation had an itraconazole MIC > 1 mg/L which is above the CLSI ECV. Eighty-six
of 89 (97%) isolates with the TR34/L98H mutation had voriconazole and posaconazole MICs above
the CLSI ECV, i.e., MICs of 1 and 0.25 mg/L, respectively. The isolates with a TR46/Y121F/T289A
mutation showed a different phenotype. All 37 isolates with a TR46/Y121F/T289A mutation had a
voriconazole MIC above the CLSI ECV, while 28/37 (76%) isolates had an itraconazole MIC > 1 mg/L.
Interestingly, only 13 of 37 (35%) isolates had a posaconazole MIC > 0.25 mg/L.
Keywords: cyp51A; aspergillosis; azole resistance; ECV; CLSI broth microdilution
1. Introduction
The triazoles, itraconazole, posaconazole, and voriconazole, are antifungal agents with potent
activity against Aspergillus fumigatus. Voriconazole is predominately used for the treatment of invasive
aspergillosis, while posaconazole is used for prophylaxis against invasive fungal infections in patients
with hematological diseases, and itraconazole is the first choice for patients with chronic pulmonary
aspergillosis. The treatment of Aspergillus infections is complicated due to the increase in antifungal
drug resistance in A. fumigatus in some geographical areas [1–3]. Azole resistance in A. fumigatus is most
frequently conferred by mutations in the cyp51A gene encoding 14α-sterol demethylases. TR34/L98H
and TR46/Y121F/T289A are the two most common mutations associated with environmental resistance
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selection. Importantly, isolates with these environmental associated mutations can be recovered from
azole-naïve patients as well as azole-treated patients [4–7]. Other common mutations such as those
at residue M220 or G54 in the cyp51A gene were associated with long-term use of azoles in a clinical
setting, especially in patients with chronic cavitary aspergillosis [8]. A recent retrospective cohort study
showed a 21% increased mortality in patients with azole-resistant invasive aspergillosis compared
to azole-susceptible infection [9]. Due to the increase in resistance and the fact that resistance can
also be found in azole-naïve patients, susceptibility testing becomes increasingly clinically relevant
for guidance of appropriate antifungal therapy [10,11]. Two reference guidelines are available for
the susceptibility testing of A. fumigatus—broth microdilution based on the Clinical and Laboratory
Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) methods [12,13]. The minimal inhibitory concentration (MIC) distributions of an extensive
number of wild-type (WT) and azole-resistant isolates were reported with the EUCAST method [14].
However, for the CLSI method, MIC distributions of a large collection of azole-resistant isolates are
not available.
We studied the MIC distributions of clinical A. fumigatus isolates to characterize the CLSI
susceptibility profiles of isolates with the WT cyp51A genotype, and isolates with the TR34/L98H and
TR46/Y121F/T289A cyp51A mutations.
2. Materials and Methods
Susceptibility data were collected for all clinical isolates cultured in the Canisius-Wilhelmina
Hospital (CWZ), Nijmegen, the Netherlands, for which susceptibility testing was performed.
Furthermore, all A. fumigatus isolates sent from other laboratories to our reference laboratory for
susceptibility testing were included in this dataset. The isolates were cultured between 2001 and 2017.
Isolates were identified as A. fumigatus based on morphological characteristics and the ability to grow
at >48 ◦C.
Susceptibility testing was performed according to CLSI M38-A2. In brief, 96-well plates (with
two-fold dilutions of antifungals) were prepared with RPMI-1680 medium with 0.2% glucose.
Inoculum suspensions were prepared in sterile 0.9% NaCl with 0.1% Tween 20. Spores were
harvested from a mature culture. The suspension was adjusted to 80–82 transmission at 530 nm
(Spectrofotometer Genesys 20) to create a 0.4–3.3 × 106 colony-forming units (CFU)/mL of spore
suspension [15]. The spore suspensions were added to the microtiter plates to create a final
concentration of 0.4 × 104–5 × 104 CFU/mL in each well. Plates were incubated for 48 h at 35 ◦C.
The lowest concentration without visible growth was used as the MIC. The concentration range
used was 0.031–16 mg/L for voriconazole, itraconazole, and posaconazole. Susceptibility testing
was repeated when non-WT azole MICs were recorded. For quality control of susceptibility testing,
Aspergillus flavus ATCC 204304, Candida parapsilosis ATCC 22019, and C. krusei ATCC 6258 were used.
The MICs of the reference strains were within the expected range.
The CLSI epidemiological cut-off values (ECVs) used were 1 mg/L for itraconazole, 1 mg/L
for voriconazole, and 0.25 mg/L for posaconazole [16,17]. All isolates with an MIC of voriconazole,
posaconazole, and/or itraconazole above these ECVs were retested and screened for tandem repeats
and point mutations, Gly54, Gly138, and Met220, in the cyp51A gene using real-time PCR [18]. When no
mutation was identified, the full cyp51A was sequenced as previously described [19].
3. Results
In total, the susceptibility of 420 isolates was available. Based on the CLSI ECVs, 265 isolates
were azole WT and 155 were characterized as non-WT [16,17]. Only one isolate per patient per six
months was included unless isolates had different susceptibility results or resistance mechanisms,
leaving a total of 363 isolates used in this study. For 33 isolates, no posaconazole MICs were available.
Of the 363 isolates, 141 isolates were phenotypically non-WT and 222 isolates had a phenotypically WT
susceptibility. In 127 of 141 (90%) phenotypically non-WT isolates, a cyp51A gene mutation could be
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identified; 88/141 (62%) had the TR34/L98H mutations [20], 37/141 (26%) had the TR46/Y121F/T289A
or TR463/Y121F/T289A mutation, and one had the TR53 mutation [21,22]. One isolate with confirmed
azole resistance had an M220V point mutation. G54 and G138 were not found in this clinical isolate
collection. For 14/141 (10%) isolates, no cyp51A mutations were detected.
The MIC distributions of voriconazole, itraconazole, and posaconazole for isolates with an azole
susceptible phenotype are displayed in Figure 1. The MIC50 and MIC90 values for these isolates are
displayed in Table 1. All isolates with the TR34/L98H mutation had an itraconazole MIC > 1 mg/L,
which is above the CLSI ECV, while 85 of 88 (97%) isolates had a voriconazole above the CLSI ECV of
MIC 1 mg/L, and 85 of 88 (97%) isolates had a posaconazole MIC above the CLSI ECV of 0.25 mg/L.
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Figure 1. Clinical and Laboratory Standards Institute (CLSI) MIC distribution of 363 clinical
isolates of Aspergillus fumigatus including 89 isolates with the TR34/L98H mutation, 37 with the
TR46/Y121F/T289A mutation, and 16 isolates with other mechanisms—1 isolate with a cyp51A point
mutation (M220V), one with a TR53 mutation, and 14 non-cyp51A azole resistance mechanisms—and
222 phenotypically wild-type isolates. MIC distributions are displayed for (a) itraconazole,
(b) voriconazole, and (c) posaconazole.
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Table 1. MIC50 and MIC90 values of itraconazole, voriconazole, and posaconazole for clinical isolates
of Aspergillus fumigatus.
Cyp51A Genotype Number
of Isolates
Itraconazole (mg/L) Voriconazole (mg/L) Posaconazole (mg/L)
MIC50 1 MIC90 1 MIC50 1 MIC90 1 MIC50 1 MIC90 1
Wild-type isolates 2 222 0.25 0.5 0.5 1 0.125 0.125
TR34/L98H 89 >16 >16 4 8 0.5 1
TR46/Y121F/T289A 37 16 >16 >16 >16 0.5 0.5
other mechanisms 16 >16 >16 2 8 0.5 0.5
1 MIC50 and MIC90 values were defined as the lowest concentration of the antifungal at which 50 and 90% of the
isolates were inhibited, respectively. 2 phenotypically wild-type isolates.
The isolates with a TR46/Y121F/T289A mutation showed a different phenotype. All isolates
had a voriconazole MIC above the CLSI ECV, while 28/37 (76%) isolates had an MIC > 1 mg/L for
itraconazole. Furthermore, 13 of 37 (35%) isolates had a posaconazole MIC > 0.25 mg/L (Figure 1).
All isolates with cyp51A resistance mutations had an MIC outside the WT range for voriconazole,
itraconazole, or posaconazole.
For 285 isolates, the sample origin was available, and the majority were isolated from sputum and
bronchial aspirates. Ninety-three of the resistant isolates were cultured from sputum and bronchial
aspirate, five were from bronchoalveolar lavage (BAL) samples, three were from sterile tissue biopsies,
and for 37 resistant isolates, the origin is unknown. For susceptible isolates, a higher proportion was
cultured from BAL or sterile tissues. The distributions are displayed in Figure 2.
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Figure 2. Pie chart showing the distribution of positive Aspergillus fumigatus cultures for sputum,
bronchoalveolar lavage (BAL), sterile tissue, and other samples. Distributions are shown for susceptible
isolates (a), and resistant isolates (b).
4. Discussion
As TR34/L98H and TR46/Y121F/T289A mutations are increasingly found worldwide, it is
important to characterize the susceptibility profile of isolates with these mutations. Such a profile
was published for the EUCAST method of susceptibility testing [14]. However, data are scarce for the
CLSI method. In this study, we characterized the MIC distributions of WT isolates and isolates with
the TR34/L98H and TR46/Y121F/T289A mutations. As expected, the CLSI susceptibility profiles in
our study were similar to the EUCAST susceptibility profiles [14]. For both EUCAST and CLSI, most
isolates with a TR34/L98H mutation had a high (>8 mg/L) MIC of itraconazole, while most of the
MICs of voriconazole were between 2 and 16 mg/L [14]. The MICs of posaconazole were between 0.25
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and 2 mg/L for both methods. The isolates with the TR46/Y121F/T289A mutation showed high MICs
of voriconazole (>8 mg/L) for both methods with variable susceptibility for itraconazole, which is in
line with a recent compilation of the literature [23]. The MICs of posaconazole were between 0.25 and
4 mg/L for both methods. Compared to WT isolates, the posaconazole MIC seems the least affected
by TR46/Y121F/T289A and TR34/L98H mutations, and the distribution of non-WT isolates overlaps
with WT isolates. In vivo models indicate that isolates with an increased posaconazole MIC may be
treatable if the posaconazole exposure is increased [24,25]. As the posaconazole MIC remains relatively
low and overlap with the WT population exists, azole-resistant aspergillosis might, in some cases, be
treated with high posaconazole dosages. Virtually no overlap of MIC distributions was observed for
itraconazole and voriconazole; however, some TR34/L98H isolates have low voriconazole MICs which
are possibly still treatable with voriconazole. In this collection, 35 of 89 (40%) had an MIC <4 mg/L.
The resistance profiles of susceptible and resistant isolates give us information on which azoles
to use for resistance screening. When only itraconazole is used for resistance screening, some
TR46/Y121F/T289A mutations will be missed as 9/37 (24%) had low MICs of itraconazole. In contrast,
when only voriconazole is used, a significant proportion of TR34/L98H resistance may be missed.
As the MIC distributions of WT and non-WT isolates overlap for posaconazole, this agent seems not
a good drug for resistance screening. However, all isolates had high levels of resistance for either
itraconazole or voriconazole. Therefore, it is advised to use a method applying a combination of
itraconazole and voriconazole, with or without the use of posaconazole (using a concentration above
the WT MIC).
As the isolates were only screened for cyp51A, mutations it is possible that some of the isolates
have additional mechanisms of azole drug tolerance, such as mutations in hapE [26,27], decreased
absorption of azoles [28], or increased expression of efflux pumps [29–31]. Possibly, such additional
resistance mechanisms explain the broad range of itraconazole MICs found for isolates with the
TR46/Y121F/T289A mutations, as well as the broad range of voriconazole MICs found for isolates
with TR34/L98H. Recently, a new resistance mutation was described with a triple TR46 promotor
repeat [27]. Additional mutations in combination with TR34/L98H were reported to be associated
with elevated MIC values of imidazole fungicides used in the environment [32]. These findings
suggest that the resistance mechanisms are continuously evolving under continued environmental
azole pressure. As we used real-time PCR [18] to detect the tandem repeats, and the G54, M220, and
G138 mutations, we only sequenced the full cyp51A gene when the four mutations were not found,
and any additional mutations in combination with TR34/L98H, TR46/Y121F/T289A, G54, M220, or
G138 were not detected.
For 285 of 363 isolates (79%), the sample origin was known. A higher proportion of susceptible
A. fumigatus isolates were cultured from sterile tissue and BAL samples compared to resistant isolates.
In an unselected collection of A. fumigatus isolates, this might reflect a higher virulence for susceptible
isolates compared to resistant isolates. However, many isolates were referred to our reference
laboratory for susceptibility testing by other laboratories. It is likely that isolates cultured from clinically
relevant sites, i.e., sterile tissue or BAL samples, are more likely to be referred for susceptibility testing
despite negative azole screening results. On the contrary, isolates that are considered less clinically
relevant are only referred when azole screening indicates resistance.
Susceptibility testing using the CLSI or EUCAST reference methods are not available in many
laboratories. Therefore, non-specialized laboratories in the Netherlands send Aspergillus isolates to
the Center of Expertise in Mycology Radboudumc/CWZ for susceptibility testing when indicated.
Furthermore, for the surveillance of antifungal resistance, many laboratories in the Netherlands
use the VIPcheck™ for screening of azole resistance [33,34]. When the screening plate indicates a
possible azole-resistant isolate, the isolates are sent to a mycology reference laboratory for in vitro
susceptibility testing. Therefore, the proportion of resistant isolates in this study does not reflect the
current resistance rate in the Netherlands. However, the large number of resistant isolates in this study
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can be used to characterize the susceptibility profile and can be used to identify the most prevalent
resistance mechanisms.
In this collection of isolates, the most common azole resistance mechanism was due to the
TR34/L98H mutation, which was also seen in a previous study with isolates from the Netherlands [14].
The TR34/L98H mechanism was the first of the environmental mutations recovered from patients [1].
Since 2009, the TR46/Y121F/T289A mutation was also found in clinical samples from the Netherlands,
but earlier isolates were found in the USA in 2008 [1,35]. This mechanism of resistance was the
second most recovered mechanism. Both resistance mechanisms were correlated with clinical failure
in retrospective case studies [1], and accounted for 87% of azole-resistant A. fumigatus isolates in a
recent cohort study, which showed a 21% excess day-42 mortality in resistance invasive aspergillosis
compared with voriconazole-susceptible infection [9].
Recently, resistance detection PCRs became available. AsperGenius, a method for the direct
molecular detection of resistance in A. fumigatus from clinical materials is commercially available.
The AsperGenius is able to identify TR34/L98H and TR46/Y121F/T289A mutations, and is validated
for BAL samples. The test was able to distinguish resistant from susceptible Aspergillus from BAL
samples, even when cultures were negative. Importantly, the detection of azole resistance with the
AsperGenius correlated with azole treatment failure [36]. Furthermore, the AsperGenius was evaluated
on plasma and serum samples; however, the sensitivity of resistance detection in these sample types
appears to be limited [37]. Another commercial resistance PCR, the MycoGENIE, has the ability
to detect TR34/L98H mutations. The assay was evaluated on samples from patients with fungal
rhinosinusitis, as well as BAL and serum samples [38,39]. Using the susceptibility data of this study, it
is possible to predict the susceptibility phenotype of itraconazole for TR34/L98H and the phenotype
of voriconazole for TR46/Y121F/T289A isolates. As voriconazole itraconazole, and posaconazole
MICs are variable for TR34/L98H and TR46/Y121F/T289A isolates using CLSI methods, it is advisable
to move away from the azole class if the resistance PCR identifies a mutation, but cultures remain
negative. However, the AsperGenius detects the TR34/L98H and TR46/Y121F/T289A mutations,
while the MycoGENIE detects only the TR34/L98H mutations, and thus, other resistance mutations
will be missed. As resistance mutations in patients with long-term azole use are more diverse and
may contain both cyp51A and non-cyp51A mechanisms, the results of molecular methods should be
carefully interpreted [40]. Hence, susceptibility testing remains paramount and molecular methods
should be used to supplement phenotypic susceptibility testing.
In conclusion, this study provides data on the susceptibility of A. fumigatus isolates using the
CLSI method and characterizes the phenotypical antifungal profile of isolates harboring TR34/L98H
and TR46/Y121F/T289A resistance mechanisms. In uncontrolled studies, an increased MIC of azoles,
as well as the detection of resistance mutations, is correlated with clinical failure, suggesting that
susceptibility testing using CLSI is an important tool to guide antifungal therapy.
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